[1]徐艺倪,王建超,王淼东,等.基于抗肺纤维化的用药规律分析新型冠状病毒肺炎的中医治疗[J].西部中医药,2022,35(06):12-16.[doi:10.12174/j.issn.2096-9600.2022.06.04]
 XU Yini,WANG Jianchao,WANG Miaodong,et al.An Analysis of TCM Therapy for COVID-19 Based on the Medication Laws of Anti-lung Fibrosis[J].Western Journal of Traditional Chinese Medicine,2022,35(06):12-16.[doi:10.12174/j.issn.2096-9600.2022.06.04]
点击复制

基于抗肺纤维化的用药规律分析新型冠状病毒肺炎的中医治疗
分享到:

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
35
期数:
2022年06期
页码:
12-16
栏目:
新冠肺炎
出版日期:
2022-06-15

文章信息/Info

Title:
An Analysis of TCM Therapy for COVID-19 Based on the Medication Laws of Anti-lung Fibrosis
作者:
徐艺倪1 王建超1 王淼东1 陈柏尧1 银艳桃1 菅若含1 邓鑫2
1.广西中医药大学,广西 南宁 530000
2.广西中医药大学附属瑞康医院
Author(s):
XU Yini1 WANG Jianchao1 WANG Miaodong1 CHEN Boyao1 YIN Yantao1 JIAN Ruohan1 DENG Xin2
1.Guangxi University of Chinese Medicine, Nanning 530000, China
2.Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine
关键词:
新型冠状病毒肺炎肺纤维化数据挖掘中医药用药规律
Keywords:
pulmonary fibrosisCOVID-19data miningtraditional Chinese medicinemedication laws
分类号:
R563.1
DOI:
10.12174/j.issn.2096-9600.2022.06.04
文献标志码:
A
摘要:
目的从数据统计中分析中医药治疗肺纤维化的用药、组方规律,为中医药治疗新型冠状病毒肺炎提供更多组方依据。 方法从中国知网(CNKI)、百度学术、维普中文期刊数据库(VIP)、万方医学数据库收集关于中药治疗肺纤维化文献中的处方,运用Microsoft Excel 2013进行频数统计、SPSS Clementine 12.0软件所提供的Apriori模版进行关联规则分析,SPSS 22.0软件进行聚类分析,以获得中医药治疗肺纤维化的用药规律。 结果共纳入204首治疗肺纤维化处方,涉及中药300味,其中使用频次≥20次的中药共40味,前五位分别是桔梗、茯苓、甘草、法半夏、黄芩。获得药对关联规则10对,包括黄芪-甘草、大枣-甘草等。3味中药关联规则8条,包括麻黄+甘草-杏仁、荆芥+金银花-连翘等。通过聚类分析得到药组12个,可做为治疗肺纤维化与新型冠状病毒肺炎的潜在配伍。 结论本研究分析所得高频中药、关联规则功效以补肺健脾、益气养阴、宣肺清肺、止咳化痰为主,并通过聚类分析得到12个治疗肺纤维化与新型冠状病毒肺炎的潜在配伍。本研究根据数据挖掘获得的用药规律、潜在配伍结合肺纤维化与新型冠状病毒肺炎病机特点,为治疗新型冠状病毒肺炎用药提供参考。
Abstract:
ObjectiveTo provide the reference for more prescription in treating COVID-19 by statistically analyzing the medications and formulation laws of TCM in treating lung fibrosis. MethodsThe prescriptions were collected in the literature on herbs in treating lung fibrosis from CNKI, Baidu scholar, VIP and Wanfang medical database, Microsoft Excel 2013 was used to perform frequency statistics, Apriori template provided by SPSS Clementine 12.0 software was applied to perform association rule analysis, so as to obtain the medication law of traditional Chinese medicine in the treatment of pulmonary fibrosis. ResultsAll 204 prescrip-tions for the treatment of pulmonary fibrosis were included, involving 300 herbs, of which 40 were used more than 20 times, the top five were Jiegeng (Radix platycodonis), Fuling (poria), licorice, processed Banxia (Rhizoma pinelliae preparatum) and Huangqin (Baical skullcap root). Ten pairs of drug pair association rules were obtained, including Huangqi (Radix astragali)-licorice, jujube-licorice and others. There were eight association rules for three herbs, containing Mahuang (Herba ephedrae)+licorice-Xingren (Bitter apricot seed), Jingjie (Herba schizonepetae)+Jinyinhua (Honeysuckle flower)-Lianqiao (Fructus forsythiae) and others. All 12 drug combina-tions obtained in cluster analysis could be chosen as the potential compatibility of treating pulmonary fibrosis and COVID-19. ConclusionThe efficacy of high frequency herbs and ssociation rules analyzed in the study is tonifying lung and invigorating spleen, benefiting Qi and nourishing Yin, dispersing and clearing lung, relieving the cough and eliminating phlegm mainly, and 12 potential combinations of treating pulmonary fibrosis and COVID-19 are obtained by cluster analysis. The study could provide the reference for the medication of COVID-19 according to the medication laws obtained in data mining, potential combination combined with the characteristics of the pathogenesis of pulmonary fibrosis and COVID-19.

相似文献/References:

[1]闫玉琴,贾琦,苏惠萍△.中医对肺纤维化病因病机的探讨[J].西部中医药,2018,31(12):23.
 YAN Yuqin,JIA Qi,SU Huiping.Exploration into the Cause and Pathogenesis of Idiopathic Pulmonary Fibrosis Based on TCM[J].Western Journal of Traditional Chinese Medicine,2018,31(06):23.
[2]李赟,王彩弟,王建云,等.简约远程中医诊疗在新型冠状病毒肺炎隔离病区中的应用[J].西部中医药,2020,33(S1):1.
 LI Yun,WANG Caidi,WANG Jianyun,et al.The Application of Simple Remote TCM Diagnosis and Treatment to COVID-19 Quarantined Inpatient Area[J].Western Journal of Traditional Chinese Medicine,2020,33(06):1.
[3]宋忠阳,雍文兴,张利英,等.新型冠状病毒肺炎的中医临床特征与辨证论治——甘肃经验*[J].西部中医药,2020,33(S1):3.
 SONG Zhongyang,YONG Wenxing,ZHANG Liying,et al.The Experience of TCM Clinical Characteristics, Syndrome Differentiation and Treatment for COVID-19 in Gansu Province[J].Western Journal of Traditional Chinese Medicine,2020,33(06):3.
[4]杜洪霖,马战平△.西北地区新型冠状病毒肺炎的中医特点及防治*[J].西部中医药,2020,33(S1):5.
 DU Honglin,MA Zhanping.TCM Characteristics, the Prevention and Treatment of COVID-19 in Northwest China[J].Western Journal of Traditional Chinese Medicine,2020,33(06):5.
[5]潘文,李盛华,王晓萍,等.中医对新型冠状病毒肺炎的认识与防治探讨[J].西部中医药,2020,33(S1):7.
 PAN Wen,LI Shenghua,WANG Xiaoping,et al.On TCM Understanding, the Prevention and Treatment of COVID-19[J].Western Journal of Traditional Chinese Medicine,2020,33(06):7.
[6]杨海侠,张银萍△,杨长虹,等.新型冠状病毒肺炎疑似患者留观隔离期的护理体会[J].西部中医药,2020,33(S1):13.
[7]丁潇,邹忆怀△,辛大永,等.北京顺义地区新型冠状病毒肺炎的中医临床证候与CT表现[J].西部中医药,2020,33(S1):16.
 DING Xiao,ZOU Yihuai,XIN Dayong,et al.TCM Clinical Syndromes and CT Manifestations of COVID-19 in Shunyi District of Beijing[J].Western Journal of Traditional Chinese Medicine,2020,33(06):16.
[8]桑天庆,周红光△.中医药在新型冠状病毒肺炎疫情中的应用[J].西部中医药,2020,33(S1):18.
 SANG Tianqing,ZHOU Hongguang.TCM Applied to Epidemic Situation of COVID-19[J].Western Journal of Traditional Chinese Medicine,2020,33(06):18.
[9]闫向勇,李 俊,燕忠生△.武汉地区新型冠状病毒肺炎中医证候及病机特点[J].西部中医药,2020,33(S1):20.
 YAN Xiangyong,LI Jun,YAN Zhongsheng.On the Characteristics of TCM Patterns and the Pathogenesis of COVID-19 in Wuhan Region[J].Western Journal of Traditional Chinese Medicine,2020,33(06):20.
[10]曾建峰,李乐愚,缪灿铭,等.岭南道地药材在中山地区新型冠状病毒肺炎防治中的应用*[J].西部中医药,2020,33(S1):24.[doi:10.1056/NEJMoa-2001017]
 and Treatment of COVID-9 in Zhongshan Region.The Application of Lingnan Genuine Drugs to the Prevention[J].Western Journal of Traditional Chinese Medicine,2020,33(06):24.[doi:10.1056/NEJMoa-2001017]

备注/Memo

备注/Memo:
徐艺倪(1994—),女,硕士学位,住院医师。研究方向:消化系统疾病的中西医结合防治。国家自然科学基金(81860790);广西自然科学基金(2017GXNSFAA198183);广西应急科技攻关专项(桂科AB20058003)。
更新日期/Last Update: 2022-06-24